Objective: Human epithelial growth factor receptor 2 (HER2) is overexpressed in several types of cancers. The correlation between tumor glucose activity and HER2 expression can vary. This study is a retrospective investigation of fluorine-18-fluorodeoxyglucose PET/computed tomography (18F-FDG PET/CT) and HER2 expression status in patients with lung adenocarcinoma.
Methods: The maximum standard uptake value (SUVmax) of 18F-FDG PET/CT was compared with the HER2 expression status in pretreated patients with lung adenocarcinoma. Moreover, clinicopathological characteristics, including age, gender, smoking, serum tumor markers, tumor location, size, stage and genetic mutation, were also evaluated in groups with different HER2 expressions. Patients' progression-free survival (PFS) and overall survival (OS) were also analyzed.
Results: Ninety-six patients with HER2 expression, including 54 patients with HER2 overexpression and 30 patients without HER2 expression were enrolled in this study. The primary pulmonary lesion was single in all patients, and all lesions were FDG-avid on PET/CT. SUVmax had no significant association with HER2 expression or overexpression in lung adenocarcinoma. Moreover, elevated serum CYFRA211 levels were obviously associated with HER2 expression but not associated with HER2 overexpression. There were no significant differences in other clinicopathological characteristics in groups with different HER2 expressions. Furthermore, multivariate Cox regression analysis revealed that SUVmax, HER2 expression and tumor node metastasis stage were independent predictors of PFS, and SUVmax, CYFRA211 and epidermal growth factor receptor mutation were independent predictors of OS.
Conclusion: SUVmax had no significant association with the HER2 expression status in lung adenocarcinoma. 18F-FDG PET/CT and HER2 expression could provide valuable prognostic information for treatment-naive patients with lung adenocarcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MNM.0000000000001530 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A promising future for breast cancer therapy with hydroxamic acid-based histone deacetylase inhibitors.
Bioorg Chem
January 2025
Department of In Vitro Carcinogenesis and Cellular Chemotherapy, Chittaranjan National Cancer Institute, 37, S. P. Mukherjee Road, Kolkata 700026, India. Electronic address:
Histone deacetylases (HDACs) play a critical role in chromatin remodelling and modulating the activity of various histone proteins. Aberrant HDAC functions has been related to the progression of breast cancer (BC), making HDAC inhibitors (HDACi) promising small-molecule therapeutics for its treatment. Hydroxamic acid (HA) is a significant pharmacophore due to its strong metal-chelating ability, HDAC inhibition properties, MMP inhibition abilities, and more.
View Article and Find Full Text PDFUnderstanding the Molecular Mechanisms of Incomptine A in Treating Non-Hodgkin Lymphoma Associated with U-937 Cells: Bioinformatics Approaches, Part I.
Pharmaceuticals (Basel)
December 2024
Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Plan de San Luis y Salvador Díaz Mirón S/N, Col. Casco de Santo Tomás, Miguel Hidalgo, Mexico City 11340, Mexico.
: Incomptine A () has been reported to have cytotoxic activity in non-Hodgkin lymphoma cancer cell lines and have effects on U-937 cells, including the induction of apoptosis, the production of reactive oxygen species, and the inhibition of glycolytic enzymes. Also, has cytotoxic activity in the triple-negative subtypes, HER2+, and luminal A of breast cancer cells, with its properties being associated with an effect on the antiapoptotic function of Hexokinase II (HKII). : In this research, we reviewed the altered levels of proteins present in the lymph nodes of male Balb/c mice inoculated with U-937 cells and treated with or methotrexate, as well as mice only inoculated with cancer cells.
View Article and Find Full Text PDFPre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer.
Int J Mol Sci
January 2025
Cancer Biotherapeutics Research Group, Life Sciences Institute, School of Biotechnology, Dublin City University, Dublin 9, D09 NR58 Dublin, Ireland.
HER2-positive/oestrogen receptor-positive (HER2+/ER+) represents a unique breast cancer subtype. The use of individual HER2- or ER-targeting agents can lead to the acquisition of therapeutic resistance due to compensatory receptor crosstalk. New drug combinations targeting HER2 and ER could improve outcomes for patients with HER2+/ER+ breast cancer.
View Article and Find Full Text PDFThe Immunohistochemical Prognostic Value of Nuclear and Cytoplasmic Silent Information Regulator 1 Protein Expression in Saudi Patients with Breast Cancer.
Biomolecules
January 2025
Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Background: The mammalian NAD-dependent deacetylase sirtuin-1 family (named also silent information regulator or SIRT family, where NAD stands for "nicotinamide adenine dinucleotide" (NAD)) appears to have a dual role in several human cancers by modulating cell proliferation and death. This study examines how SIRT1 protein levels correlate with clinicopathological characteristics and survival outcomes in patients with breast cancer.
Methods: A total of 407 BC formalin-fixed paraffin-embedded (FFPE) samples were collected from King Abdulaziz University Hospital, Saudi Arabia.
A Comprehensive Analysis of Neoadjuvant Chemotherapy in Breast Cancer: Adverse Events, Clinical Response Rates, and Surgical and Pathological Outcomes-Bozyaka Experience.
Cancers (Basel)
January 2025
Bozyaka Education and Research Hospital, University of Health Sciences Turkey, 35170 Izmir, Turkey.
To evaluate the neoadjuvant chemotherapy (NACTx) process in breast cancer (BC), its significant treatment-related adverse events (trAEs), tumor clinical response rates, and surgical and pathological outcomes, and to analyze factors influencing cavity shaving and axillary lymph node dissection (ALND) following sentinel lymph node biopsy (SLNB). A comprehensive retrospective study was conducted at a single center on patients who received NACTx for BC between 2015 and 2021. Medical records of 242 patients were reviewed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!